From: Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
 | Tests employed | References | ||
---|---|---|---|---|
Age ≤ 36 months | BSID-III | MSEL | GMDS-III |  |
 Rangea | 0–42 months | 0–68 months | 0–72 months |  |
 Natural history, MPS characteristic studies | MPS I, II, III | MPS I, II, III | MPS III | |
 Treatment outcome | MPS I (HSCT), MPS II (ERT); MPS IIIA (IT-ERT) | MPS I (HSCT) | MPS I (HSCT, ERT), MPS II (HSCT, ERT), MPS III (HSCT) | |
Age > 36 months, ≤ 6 years | KABC-II | Leiter-III | WPPSI-IV |  |
 Rangea | 3–18 years | 3–75 years | 2.6–7.7 years |  |
 Natural history, MPS characteristic studies | MPS III | – | MPS I, II | |
 Treatment outcome | – | MPS I ((HSCT), MPS III (HSCT) | MPS I (HSCT) | |
Age > 6 years and adulthood | WISC-IV | WAIS-IV | WASI |  |
 Rangea | 6.0–16.11 years | 16–90 years | 6–89 years |  |
 Natural history, MPS characteristic studies | MPS II, III | MPS I, II, III | MPS I, II | |
 Treatment outcome | MPS I (HSCT) | MPS I (HSCT) | MPS I (HSCT) |